MiniMed Group

Update in progress

MMED (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryMedical Instruments & Supplies

Minimed Group, Inc. is a medical technology company that develops, manufactures, and markets devices for diabetes management. Its offerings include insulin delivery devices (pumps and pens), continuous glucose monitors, consumables, software, and services. It serves people on insulin therapy—primarily those with type 1 diabetes and many with type 2. The platform includes Automated Insulin Delivery systems and Smart MDI products such as InPen, Simplera, and Guardian 4, plus services. Founded 1983, headquartered in Northridge, California. Independent of Medtronic Global Holdings S.C.A. as of March 25, 2026.

Company score

Sentiment: 0.13; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.00; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.15; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.03; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.05; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive